C-Reactive Protein to Albumin Ratio is an Indicator of Poor Prognosis for Patients with Biliary Tract Cancer

Basit Öğe Kaydı
dc.authoridDEMİR, TARIK/0000-0001-6334-4079
dc.authoridAraz, Murat/0000-0002-4632-9501;
dc.authorwosidDEMİR, TARIK/AAA-5670-2020
dc.authorwosidAraz, Murat/C-6388-2015
dc.authorwosidAliyev, Altay/JVY-9357-2024
dc.contributor.authorDemir, Tarik
dc.contributor.authorKostek, Osman
dc.contributor.authorAraz, Murat
dc.contributor.authorSakin, Abdullah
dc.contributor.authorAliyev, Altay
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorTurk, Haci Mehmet
dc.date.accessioned2024-06-12T10:54:30Z
dc.date.available2024-06-12T10:54:30Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives: This retrospective study evaluated the prognostic significance of the ratio of C-reactive protein (CRP) to albumin (Alb) in patients with biliary tract cancer (BTC). Methods: A total of 178 patients with newly diagnosed BTC, who had been treated in our departments between January 2013 and September 2018, were enrolled in the study. All medical records were reviewed retrospectively. Patients who showed clinical evidence of infection or other inflammatory conditions were excluded. We investigated the correlation between the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), CRP to Alb ratio (CAR) and the overall survival (OS) rates for BTC patients. Both univariate and multivariate analyses were performed to identify clinicopathological variables associated with OS. Results: The optimal cutoff level for the CAR was 0.66. An elevated CAR was associated with low OS (p<0.001). In the multivariate analysis CAR, was independently associated with OS (HR 3.44, 95% CI: 2.05-5.79, p<0.001). Median OS for CAR <= 0.66 and CAR >0.66 were 22.0 months and 6.0 months, respectively. By contrast, NLR (p=0.12) and PLR (p=0.85) were not independently associated with OS. Conclusion: The CAR might be an independent prognostic marker for patients with BTC, and might have value comparable with other established inflammation-based prognostic scores. The prognostic value of this novel inflammation-based prognostic score needs to be verified in patients with other types of cancer.en_US
dc.identifier.doi10.14744/ejmo.2019.74396
dc.identifier.endpage70en_US
dc.identifier.issn2587-196X
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85100320285en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage65en_US
dc.identifier.trdizinid330103en_US
dc.identifier.urihttps://doi.org/10.14744/ejmo.2019.74396
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/330103
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19079
dc.identifier.volume4en_US
dc.identifier.wosWOS:000604252800009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEurasian Journal Of Medicine And Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiliary Tract Canceren_US
dc.subjectC-Reactive Protein To Albumin Ratioen_US
dc.subjectNeutrophil To Lymphocyte Ratioen_US
dc.subjectPlatelet To Lymphocyte Ratioen_US
dc.subjectPrognostic Scoreen_US
dc.subjectProtein/Albumin Ratioen_US
dc.subjectLymphocyte Ratioen_US
dc.subjectSurvivalen_US
dc.subjectNeutrophilen_US
dc.subjectOutcomesen_US
dc.subjectScoreen_US
dc.titleC-Reactive Protein to Albumin Ratio is an Indicator of Poor Prognosis for Patients with Biliary Tract Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu